A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
Clinical trial NCT06362044 · COMPLETED
Trial details
- NCT number
- NCT06362044
- Sponsor
- AbbVie
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2023-06-07
- Primary completion
- 2024-12-31
- Enrollment
- 89
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.